Format

Send to

Choose Destination
See comment in PubMed Commons below
Langenbecks Arch Surg. 2009 Nov;394(6):1073-8. doi: 10.1007/s00423-008-0435-y. Epub 2008 Nov 20.

Conversion to sirolimus of patients with chronic allograft nephropathy--a retrospective analysis of outcome and influencing factors.

Author information

1
Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. oliver.witzke@uk-essen.de

Abstract

PURPOSE:

The purpose of this study was to analyse the outcome and its influencing factors in patients whose therapy was converted from calcineurin inhibitors (CNI) to sirolimus (SRL) due to chronic allograft nephropathy (CAN).

MATERIALS AND METHODS:

Therapies of 78 patients (44 men) with CAN from three European transplant centres were converted from CNI therapy to SRL and followed 24 months. Slopes for creatinine clearance before and after conversion were calculated. Influencing factors were analysed by a multivariance analysis.

RESULTS:

The slope of the creatinine clearance improved significantly (-0.90 vs. -0.34 ml min(-1) month(-1); p < 0.01). In patients whose therapy was converted from cyclosporine A (CyA) to SRL, the slope improved significantly, whereas conversion from Tacrolimus (Tac) to SRL did not affect the slope. The benefit was more pronounced in (1) patients with low or moderate baseline creatinine clearance, (2) patients receiving SRL after conversion without additional mycophenolate mofetil and (3) patients with low or moderate proteinuria.

CONCLUSION:

Conversion from CyA to SRL but not from Tac to CRL is associated with a reduced loss of renal allograft function in patients with CAN.

PMID:
19020895
DOI:
10.1007/s00423-008-0435-y
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center